Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Sep 14

PMID 30211110

Citations 10

Authors

Jingquan Jia

Michael A Morse

Rebecca J Nagy

Richard B Lanman

John H Strickler

Affiliations

Soon will be listed here.

Abstract

amplification is rare in treatment-naïve metastatic colorectal cancer (CRC) tumors, but can emerge as a mechanism of resistance to anti-EGFR therapies. Preclinical and clinical data suggest that patients with amplified tumors benefit from MET-targeted therapy. Cabozantinib is an inhibitor of multiple tyrosine kinases, included c-MET. Panitumumab is an inhibitor of EGFR. This report describes a patient with , and wild-type metastatic CRC who experienced disease progression on all standard chemotherapy and anti-EGFR antibody therapy. The patient was enrolled in a clinical trial evaluating the combination of cabozantinib plus panitumumab. After only 6 weeks of treatment, the patient experienced a significant anti-tumor response. Although tumor tissue was negative for amplification, molecular profiling of cell-free DNA (cfDNA) revealed amplification. This case represents the first report showing the activity of cabozantinib in combination with panitumumab in a patient with metastatic CRC, and suggests that amplification in cfDNA may be a biomarker of response. A clinical trial targeting amplified metastatic CRC is currently underway.

Citing Articles

A panorama of colon cancer in the era of liquid biopsy.

Devalle S, Aran V, Bastos Junior C, Pannain V, Brackmann P, Gregorio M J Liq Biopsy. 2025; 4:100148.

PMID: 40027146 PMC: 11863817. DOI: 10.1016/j.jlb.2024.100148.

A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer.

Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M J Gastrointest Cancer. 2024; 56(1):29.

PMID: 39652198 DOI: 10.1007/s12029-024-01156-x.

Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.

Gmeiner W Cancers (Basel). 2024; 16(5).

PMID: 38473386 PMC: 10930828. DOI: 10.3390/cancers16051029.

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).

Scott A, Basu Mallick A, Dotan E, Cohen S, Gold P, Hochster H Cancer Res Commun. 2023; 2(10):1188-1196.

PMID: 36969746 PMC: 10035393. DOI: 10.1158/2767-9764.CRC-22-0169.

Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies.

Debattista J, Grech L, Scerri C, Grech G Int J Mol Sci. 2023; 24(2).

PMID: 36675253 PMC: 9866722. DOI: 10.3390/ijms24021738.

References

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J . Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3(99):99ra86. PMC: 3268675. DOI: 10.1126/scitranslmed.3002442. View

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C . Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008; 99(1):83-9. PMC: 2453041. DOI: 10.1038/sj.bjc.6604439. View

Janku F, Angenendt P, Tsimberidou A, Fu S, Naing A, Falchook G . Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015; 6(14):12809-21. PMC: 4494976. DOI: 10.18632/oncotarget.3373. View

Maroun C, Rowlands T . The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014; 142(3):316-38. DOI: 10.1016/j.pharmthera.2013.12.014. View

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M . Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18(2):221-3. DOI: 10.1038/nm.2609. View

Trusolino L, Bertotti A, Comoglio P . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010; 11(12):834-48. DOI: 10.1038/nrm3012. View

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O . Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol. 2011; 25(1):122-30. DOI: 10.1038/modpathol.2011.143. View

Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V . MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 2014; 74(6):1857-69. DOI: 10.1158/0008-5472.CAN-13-2340-T. View

Tang C, Fontes Jardim D, Falchook G, Hess K, Fu S, Wheler J . MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2015; 1(1):5-13. PMC: 4295762. DOI: 10.18632/oncoscience.3. View

10.

Bean J, Brennan C, Shih J, Riely G, Viale A, Wang L . MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-7. PMC: 2409244. DOI: 10.1073/pnas.0710370104. View

11.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

12.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D . Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486(7404):532-6. PMC: 3927413. DOI: 10.1038/nature11156. View

13.

Belilovski Rozenblum A, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S . Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. J Thorac Oncol. 2016; 12(2):258-268. DOI: 10.1016/j.jtho.2016.10.021. View

14.

Boccaccio C, Luraghi P, Comoglio P . MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer Res. 2014; 74(14):3647-51. DOI: 10.1158/0008-5472.CAN-14-1088. View

15.

Maina F, Pante G, Helmbacher F, Andres R, Porthin A, Davies A . Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell. 2001; 7(6):1293-306. DOI: 10.1016/s1097-2765(01)00261-1. View

16.

Kim S, Banks K, Lee S, Kim K, Park J, Park S . Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precis Oncol. 2020; 1. PMC: 7446388. DOI: 10.1200/PO.16.00059. View

17.

Schildhaus H, Schultheis A, Ruschoff J, Binot E, Merkelbach-Bruse S, Fassunke J . MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2014; 21(4):907-15. DOI: 10.1158/1078-0432.CCR-14-0450. View

18.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

19.

Ko B, He T, Gadgeel S, Halmos B . MET/HGF pathway activation as a paradigm of resistance to targeted therapies. Ann Transl Med. 2017; 5(1):4. PMC: 5253284. DOI: 10.21037/atm.2016.12.09. View

20.

Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen D, Chaganti R . Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res. 1990; 50(19):6417-22. View